Testosterone for Men With Insulin Treated Type 2 Diabetes - Full Text View

Sponsor:	Barnsley Hospital
Information provided by:	Barnsley Hospital
ClinicalTrials.gov Identifier:	NCT00349362

Purpose

The purpose of this study is to test the effect of testosterone treatment on glycaemic control, arterial stiffness and IMT in hypogonadal men with type 2 diabetes treated with insulin.

Condition	Intervention	Phase
Hypogonadism Diabetes	Drug: Testosterone Drug: 0.9% saline	Phase IV

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment
Official Title:	A Randomised Double Blind Placebo Controlled, Parallel Pilot Study to Test the Effect of Testosterone Replacement on Glycaemic Control and Arterial Wall Properties of Hypogonadal Men With Type 2 Diabetes Treated With Insulin

Resource links provided by NLM:

Genetics Home Reference related topics: 6q24-related transient neonatal diabetes mellitus

MedlinePlus related topics: Diabetes Diabetes Medicines Diabetes Type 2

Drug Information available for: Testosterone Propionate Methyltestosterone Testosterone Insulin Oxymesterone Testosterone enanthate Testosterone undecanoate

U.S. FDA Resources

Further study details as provided by Barnsley Hospital:

Primary Outcome Measures:

The effect of 6 months of testosterone replacement on diabetes control measured by HbA1c in hypogonadal men with type 2 diabetes treated with insulin. [ Time Frame: 6 months ]

Secondary Outcome Measures:

The effect of testosterone on ultrasound measured intima-media thickness of the common carotid artery in the study population [ Time Frame: 6 months ]
The effect of testosterone on male hypogonadism as assessed by the Ageing Males Symptoms (AMS) [ Time Frame: 6 months ]
The effect of testosterone on markers of vascular risk; blood pressure, serum lipid levels, weight, waist circumference, body fat percentage, [ Time Frame: 6 months ]
urinary micro-albumin, tumour necrosis factor alpha, and highly sensitive C reactive protein levels in the study population. [ Time Frame: 6 months ]
The effect of the CAG repeat polymorphism in exon 1 of the androgen receptor gene on the response of the study population to testosterone. [ Time Frame: 6 months ]

Estimated Enrollment:	40
Study Start Date:	July 2006
Study Completion Date:	October 2008
Primary Completion Date:	October 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Testosterone Testosterone injections- 200mg- every 2 weeks	Drug: Testosterone Sustanon- 200mg intramuscular testosterone
Placebo Comparator: Placebo Normal saline injections- every two weeks	Drug: 0.9% saline Saline intramuscular injection every two weeks

Detailed Description:

There is epidemiological data linking low serum testosterone levels in men with the development of diabetes. Clinical trials have indicated a potential benefit of testosterone treatment in improving diabetic control and insulin resistance. Type 2 diabetes is also associated with changes in arterial stiffness and IMT which are known to be linked to the presence of cardiovascular disease. Artificially induced hypogonadism results in increasing arterial stiffness whilst testosterone is known to improve risk factors for vascular disease and act as a vasodilator. The purpose of this pilot study is to test the effect of six months of testosterone replacement, given as testosterone esters 200mg from Sustanon 250 IM injection, on diabetes control in hypogonadal men with type 2 diabetes treated with insulin.

Eligibility

Ages Eligible for Study:	40 Years and older
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

males over 40 years old
type 2 diabetes treated with insulin
serum testosterone less than 12nmol/L on 2 consecutive morning samples
symptoms attributable to hypogonadism

Exclusion Criteria:

current or previous breast cancer
current or previous prostate cancer
raised prostate specific antigen or abdominal digital rectal examination suspicious of prostate cancer unless diagnosis excluded after specialist urology opinion and/or prostate biopsy
severe symptoms of benign prostatic hypertrophy
treatment with testosterone in the three months prior to the trial
investigational drug treatment in the three months prior to the trial

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00349362

Locations

United Kingdom
Barnsley Hospital NHS Foundation Trust
Barnsley, South Yorkshire, United Kingdom, S75 2EP

Sponsors and Collaborators

Barnsley Hospital

Investigators

Principal Investigator:

Hugh Jones, BSc MD FRCP

Barnsley Hospital NHS Foundation Trust

More Information

No publications provided

Responsible Party:	Prof Hugh Jones, Barnsley Hospital NHS Foundation Trust
ClinicalTrials.gov Identifier:	NCT00349362 History of Changes
Other Study ID Numbers:	BDGH 264
Study First Received:	July 6, 2006
Last Updated:	March 29, 2010
Health Authority:	United Kingdom: National Health Service

Additional relevant MeSH terms:

Diabetes Mellitus
Diabetes Mellitus, Type 2
Hypogonadism
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Gonadal Disorders
Testosterone
Testosterone enanthate
Testosterone undecanoate
Testosterone 17 beta-cypionate

Methyltestosterone
Androgens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Therapeutic Uses
Anabolic Agents

ClinicalTrials.gov processed this record on February 09, 2012